DIFFERENTIAL DIAGNOSIS USING MOXO

CASE STUDY COURTESY OF DR. VISHNE, EXPERT PSYCHIATRIST

BACKGROUND:

Nathan is a 22-year-old male student, suffering from low self-esteem and whose grades are lagging behind. In the process of psychiatric assessment anxiety was diagnosed as well as ADHD symptoms.

SCREENING:

In Nathan's first visit to his psychiatrist, he was administered a MOXO CPT test. Results showed a tendency toward attention deficit. An hour later Nathan did a second test this time under MPH. A comparative report between the two tests didn't show any significant improvement.
Based on these findings the psychiatrist recommended Nathan a six-week trial using SSRI only. At the end of this. Nathan was invited for a third MOXO test under as SSRI only which didn't show any improvement as well.

Lastly a combination of SSRI and MPH was recommended. Nathan did another MOXO test, and the results showed a meaningful improvement in the patient system symptoms in comparison to the previous test performed.

Dr. Vishne, explained that monitoring the patient and evaluating the efficacy of the treatment given to him is very crucial and sometimes even more important than the initial diagnosis as it may help in differential diagnosis. The drug treatment approved to be very helpful and promoting Nathan's scholastic achievement and in enhancing his self-image. Nathan has continued to develop successfully both academically and socially.

About the advisor: Dr. Tali Vishne is an expert psychiatrist senior lecturer of nearer psychiatry, head of a center that offers full psychological and psychiatric evaluation treatment and rehabilitation.

# CLINICAL DECISION SUPPORT (TALI VISHNE, M.D)

MEDICATION SELECTION – I

Patient code: 407609 | Male | 22Y | Test Date: March 2014 / Symptoms: Attention and Anxiety

UN MEDICATED

Examinee Type: A4s4 T4s4 I4s4 H4s4

	A	T	I	H
1				
2				
3				
4	-10.465	-7.58	-5.774	-11.256

SEVERITY TABLE

ATTENTION	TIMING	IMPULSIVENESS	HYPERACTIVITY
4	4	4	4

Major Severity — Minor Severity

MPH 30MG

Examinee Type: A4s4 T4s4 I4s3 H4s4

	A	T	I	H
1				
2				
3				
4	-5.191	-3.26	-2.41	-5.731

SEVERITY TABLE

ATTENTION	TIMING	IMPULSIVENESS	HYPERACTIVITY
4	4	3	4

Major Severity — Minor Severity

CLINICAL INTERPRETATION: NO SIGNIFICANT DRUG EFFECT / PROVIDER MOVED TO ADDRESS ANXIETY SYMPTOMS

MEDICATION SELECTION – II

Patient code: 407609 | Male | 22Y | Test Date: April 2014 / During 6-week trial of SSRI with anxiolytic effects

SCREENING: SSRI ONLY

Examinee Type: A4s4 T4s4 I4s4 H4s4

	A	T	I	H
1				
2				
3				
4	-7.828	-4.818	-2.859	-7.573

SEVERITY TABLE

ATTENTION	TIMING	IMPULSIVENESS	HYPERACTIVITY
4	4	4	4

Major Severity — Minor Severity

SSRI + MPH 30MG

Examinee Type: A4s4 T4s4 I4s3 H4s4

	A	T	I	H
1			0.000	0.000
2				
3	-1.337			
4		-2.198		

SEVERITY TABLE

TIMING
2

Major Severity — Minor Severity

SYMPTOMS NOT ANXIETY- OR DEPRESSION-DRIVEN

MPH FORMULATION WITH SSRI SHOWS EFFECT